A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production

Nature Communications

Volumn 6, Issue , 2015, Pages

  Nachbur, Ueli ^a,b   Stafford, Che A ^a,b   Bankovacki, Aleksandra ^a,b   Zhan, Yifan ^a,b   Lindqvist, Lisa M ^a,b   Fiil, Berthe K ^c,d   Khakham, Yelena ^a,b   Ko, Hyun Ja ^a,b   Sandow, Jarrod J ^a,b   Falk, Hendrik ^a,b,e   Holien, Jessica K ^f   Chau, Diep ^a,b   Hildebrand, Joanne ^a,b   Vince, James E ^a,b   Sharp, Phillip P ^a,b   Webb, Andrew I ^a,b   Jackman, Katherine A ^g   Mühlen, Sabrina ^b   Kennedy, Catherine L ^b   Lowes, Kym N ^a,b   Murphy, James M ^a,b   Gyrd Hansen, Mads ^c,d   Parker, Michael W ^f,h   Hartland, Elizabeth L ^b   Lew, Andrew M ^a,b   Huang, David C S ^a,b   Lessene, Guillaume ^a,b   Silke, John ^a,b   more..

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c University of Copenhagen   (Denmark)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Cancer Therapeutics CRC   (Australia)

^f ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^g FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CCR2; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; RANTES; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; WEHI 345; ADENOSINE TRIPHOSPHATE; CYTOKINE; PROTEIN BINDING; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; RIPK2 PROTEIN, HUMAN; RIPK2 PROTEIN, MOUSE; UBIQUITIN;

ANTIGEN; ENZYME ACTIVITY; IMMUNE RESPONSE; PROTEIN; RODENT; SIGNALING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; GENETICS; HUMAN; IC50; IMMUNE SYSTEM; INFLAMMATION; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; NONOBESE DIABETIC MOUSE; PROTEIN CONFORMATION; TANDEM MASS SPECTROMETRY;

BACTERIA (MICROORGANISMS); MUS;

ADENOSINE TRIPHOSPHATE; ANIMALS; CHROMATOGRAPHY, LIQUID; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INHIBITORY CONCENTRATION 50; INTERFERON-GAMMA; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; NF-KAPPA B; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; UBIQUITIN;

EID: 84925003052     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7442     Document Type: Article

References (50)

1. Chamaillard, M. et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4, 702-707 (2003).
2. Girardin, S. E. et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300, 1584-1587 (2003).
3. Girardin, S. E. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872 (2003).
4. Hruz, P. et al. NOD2 contributes to cutaneous defense against Staphylococcus aureus through alpha-toxin-dependent innate immune activation. Proc. Natl Acad. Sci. USA 106, 12873-12878 (2009).
5. Kobayashi, K. et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416, 194-199 (2002).
6. Viala, J. et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 5, 1166-1174 (2004).
7. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
8. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
9. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
10. Henckaerts, L. & Vermeire, S. NOD2/CARD15 disease associations other than Crohn's disease. Inflamm. Bowel Dis. 13, 235-241 (2007).
11. Shaw, P. J. et al. Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity 34, 75-84 (2011).
12. Ogura, Y. et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J. Biol. Chem. 276, 4812-4818 (2001).
13. Travassos, L. H. et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11, 55-62 (2010).
14. Hasegawa, M. et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J. 27, 373-383 (2008).
15. Magalhaes, J. G. et al. Essential role of Rip2 in the modulation of innate and adaptive immunity triggered by Nod1 and Nod2 ligands. Eur. J. Immunol. 41, 1445-1455 (2011).
16. Bertrand, M. J. et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30, 789-801 (2009).
17. Damgaard, R. B. et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol. Cell 46, 746-758 (2012).
18. Fiil, B. K. et al. OTULIN restricts Met1-linked ubiquitination to control innate immune signaling. Mol. Cell 50, 818-830 (2013).
19. Inohara, N., del Peso, L., Koseki, T., Chen, S. & Nunez, G. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J. Biol. Chem. 273, 12296-12300 (1998).
20. McCarthy, J. V., Ni, J. & Dixit, V. M. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J. Biol. Chem. 273, 16968-16975 (1998).
21. Thome, M. et al. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr. Biol. 8, 885-888 (1998).
22. Tigno-Aranjuez, J. T., Asara, J. M. & Abbott, D. W. Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. Genes Dev. 24, 2666-2677 (2010).
23. Lu, C. et al. Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity. J. Biol. Chem. 280, 16278-16283 (2005).
24. Nembrini, C. et al. The kinase activity of Rip2 determines its stability and consequently Nod1-and Nod2-mediated immune responses. J. Biol. Chem. 284, 19183-19188 (2009).
25. Dorsch, M. et al. Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2. Cell. Signal. 18, 2223-2229 (2006).
26. Windheim, M., Lang, C., Peggie, M., Plater, L. A. & Cohen, P. Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem. J. 404, 179-190 (2007).
27. Argast, G. M., Fausto, N. & Campbell, J. S. Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol. Cell. Biochem. 268, 129-140 (2005).
28. Xie, T. et al. Structural basis of RIP1 inhibition by necrostatins. Structure 21, 493-499 (2013).
29. Laskowski, R. A., Moss, D. S. & Thornton, J. M. Main-chain bond lengths and bond angles in protein structures. J. Mol. Biol. 231, 1049-1067 (1993).
30. Zhang, D., Lin, J. & Han, J. Receptor-interacting protein (RIP) kinase family. Cell. Mol. Immunol. 7, 243-249 (2010).
31. Meylan, E. & Tschopp, J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci. 30, 151-159 (2005).
32. Festjens, N., Vanden Berghe, T., Cornelis, S. & Vandenabeele, P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Differ. 14, 400-410 (2007).
33. Murphy, J. M. et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443-453 (2013).
34. Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213-227 (2012).
35. Zhao, J. et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc. Natl Acad. Sci. USA 109, 5322-5327 (2012).
36. Ong, S. E. et al. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc. Natl Acad. Sci. USA 106, 4617-4622 (2009).
37. Yang, Y. et al. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J. Biol. Chem. 282, 36223-36229 (2007).
38. Bertrand, M. J. et al. cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin chains to receptor interacting proteins kinases 1 to 4 (RIP1-4). PLoS ONE 6, e22356 (2011).
39. Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693 (2007).
40. Vince, J. E. et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 36, 215-227 (2012).
41. Hsu, H., Huang, J., Shu, H. B., Baichwal, V. & Goeddel, D. V. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4, 387-396 (1996).
42. Krieg, A. et al. XIAP mediates NOD signalling via interaction with RIP2. Proc. Natl Acad. Sci. USA 106, 14524-14529 (2009).
43. Nachbur, U., Vince, J. E., O'Reilly, L. A., Strasser, A. & Silke, J. Is BID required for NOD signalling? Nature 488 E4-6; discussion E6-8 (2012).
44. Damgaard, R. B. et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol. Med. 5, 1278-1295 (2013).
45. Sali, A. & Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (1993).
46. Wisniewski, J. R., Zougman, A. & Mann, M. Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J. Proteome Res. 8, 5674-5678 (2009).
47. Hammer, M. et al. Control of dual-specificity phosphatase-1 expression in activated macrophages by IL-10. Eur. J. Immunol. 35, 2991-3001 (2005).
48. Hohl, T. M. et al. Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection. Cell Host Microbe 6, 470-481 (2009).
49. Hjerpe, R. et al. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 10, 1250-1258 (2009).
50. Ko, H. J. et al. Transplantation of autoimmune regulator-encoding bone marrow cells delays the onset of experimental autoimmune encephalomyelitis. Eur. J. Immunol. 40, 3499-3509 (2010).